Gambro enters into Joint Venture in Connecticut

Gambro enters into Joint Venture in Connecticut Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that its wholly owned US subsidiary, GAMBRO Healthcare, Inc., has entered into a joint venture with Backus Dialysis Corporation, a wholly owned subsidiary of The William W. Backus Hospital, to provide dialysis services to over 115 patients in the Norwich, Connecticut area at the outpatient dialysis clinic located on the Hospital's campus. Dialysis treatment and related patient services will continue to be under the supervision of the medical directors affiliated with Southeastern Connecticut Nephrology Associates, P.C. This new joint venture is in addition to a previous venture with The William W. Backus Hospital and Lawrence and Memorial Hospital to provide dialysis services in New London, Connecticut. With this transaction, Gambro maintains its position as the leading provider of renal care services in that state. "Gambro's decision to enter the joint venture is in line with the company's strategic plan to develop dialysis services throughout the state of Connecticut. Backus Dialysis Corporation and Southeastern Connecticut Nephrology Associates, P.C. have a strong reputation for providing quality dialysis treatment to patients in the Norwich, Connecticut area," stated Mats Wahlström, President of GAMBRO Healthcare. GAMBRO Healthcare, Inc. is a wholly owned subsidiary of Gambro AB, a world- leading medical technology and healthcare company. GAMBRO Healthcare is a fully integrated service provider in renal replacement therapy. Its activities include risk contracting, disease management, physician practice management, dialysis services, and clinical laboratory services. GAMBRO Healthcare is the third largest provider of kidney dialysis services in the US. The Company now owns, operates, manages or provides consulting services to 480 dialysis centers in the United States. Through these dialysis centers Gambro now serves about 35,900 patients in centers across 33 states and the District of Columbia. For further information please contact: Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00, +46-70-513 65 33 Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35, +46-70-513 65 34 Tim Schoenberg, Vice President, US Investor Relations Manager, +1-949-425-2185 Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is one of the leading providers of kidney dialysis services in the world. Gambro treats about 43,200 patients in 581 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis concentrates. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/11/02/19991102BIT00170/bit0001.doc http://www.bit.se/bitonline/1999/11/02/19991102BIT00170/bit0002.pdf